the Pediatric Committee of the European Medicines Agency made positive decisions
In September, the Pediatric Committee of the European Medicines Agency made positive decisions on plans for a study in pediatric medicine, including Sildenafil Citrate (EMEA-C-000671-PIP01-09-M10) from Pfizer Limited, for the treatment of pulmonary arterial hypertension (PAH).
The purpose of the study is to build the required quality, safety and efficacy data through research to support the authorization of medicines for children of all ages.